Does Chromophobe Renal Cell Carcinoma Have Better Survival Than Clear Cell Renal Cell Carcinoma? A Clinical-based Cohort Study and Meta-analysis

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2015 Nov 22

PMID 26589610

Citations 11

Authors

Hui-Ming Jiang

Jin-Huan Wei

Zhi-Ling Zhang

Yong Fang

Bang-Fen Zhou

Zhen-Hua Chen

Jun Lu

Bing Liao

Fang-Jian Zhou

Jun-Hang Luo

Wei Chen

Affiliations

Soon will be listed here.

Abstract

Background: It is controversial whether chromophobe renal cell carcinoma (chRCC) or clear cell renal cell carcinoma (ccRCC) is associated with better survival. We conducted a clinical-based cohort study and meta-analysis to evaluate the prognostic role of histology between chRCC and ccRCC.

Methods: A cohort of 1540 patients (166 with chRCC and 1374 with ccRCC) were selected from Sun Yat-sen University and The Cancer Genome Atlas databases. The clinicopathological parameters and overall survival (OS) were compared between patients with chRCC and those with ccRCC. For the meta-analysis, we searched the PubMed, Cochrane Library, and Ovid databases for studies comparing OS or cancer-specific survival (CSS) between chRCC and ccRCC.

Results: The cohort study revealed that patients with chRCC were younger (median 52 vs. 55 years, P < 0.001), were more commonly female (47.0 vs. 33.0%, P < 0.001), and had a larger tumor size (mean 7.1 vs. 5.9 cm, P < 0.001), and they had a lower stage compared with those with ccRCC. Five-year OS rates for chRCC and ccRCC were 90.3 and 75.3%, respectively (P < 0.001). We found significantly better survival for chRCC in stratification analysis by age, sex, tumor size, and stage. Similar results were observed on both univariate [hazard ratio (HR), 0.30; 95% confidence interval (CI) 0.16-0.55, P < 0.001] and multivariate analyses (HR 0.42; 95% CI 0.23-0.79, P = 0.006). Ten studies were included in our meta-analysis. Eight of them provided data on univariate analysis. The pooled HR was statistically significant for OS (pooled HR 0.49; 95% CI 0.30-0.79, P = 0.004) and CSS (pooled HR 0.49; 95% CI 0.37-0.64, P < 0.001). Seven studies reported the HR on multivariate analysis. The pooled HR was also statistically significant for OS (pooled HR 0.63; 95% CI 0.51-0.77, P < 0.001) and CSS (pooled HR 0.72; 95 % CI 0.57-0.90, P = 0.003). These data indicate that patients with chRCC had better outcomes than those with ccRCC.

Conclusions: Our large cohort study and meta-analysis confirmed that chRCC had better survival than ccRCC.

Citing Articles

Development and validation of nomograms predicting postoperative survival in patients with chromophobe renal cell carcinoma.

Li S, Zhu J, He Z, Ashok R, Xue N, Liu Z Front Oncol. 2022; 12:982833.

PMID: 36452499 PMC: 9701834. DOI: 10.3389/fonc.2022.982833.

Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.

Maughan B Curr Oncol Rep. 2022; 24(9):1201-1208.

PMID: 35438388 PMC: 9468090. DOI: 10.1007/s11912-022-01269-1.

Circ_RPL23A acts as a miR-1233 sponge to suppress the progression of clear cell renal cell carcinoma by promoting ACAT2.

Cheng L, Cao H, Xu J, Xu M, He W, Zhang W J Bioenerg Biomembr. 2021; 53(4):415-428.

PMID: 34036483 DOI: 10.1007/s10863-021-09901-8.

Multi-Phase Multiple Detector Computed Tomography (MDCT) Enhancement Patterns and Morphological Features of Chromophobe Renal Cell Carcinoma: An Analysis of 67 Cases.

Luo M, Zhu Y, Chen S, Huang Q, Zhang W, Ma M Med Sci Monit. 2021; 27:e929287.

PMID: 33907175 PMC: 8091903. DOI: 10.12659/MSM.929287.

Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma.

Neves J, Vanaclocha Saiz L, Abu-Ghanem Y, Marchetti M, Tran-Dang M, El-Sheikh S World J Urol. 2021; 39(10):3823-3831.

PMID: 33851271 DOI: 10.1007/s00345-021-03683-9.

References

Klatte T, Han K, Said J, Bohm M, Allhoff E, Kabbinavar F . Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol. 2008; 26(6):604-9. DOI: 10.1016/j.urolonc.2007.07.015. View

Yusenko M . Molecular pathology of chromophobe renal cell carcinoma: a review. Int J Urol. 2010; 17(7):592-600. DOI: 10.1111/j.1442-2042.2010.02558.x. View

Katz M, Serrano M, Humphrey P, Grubb 3rd R, Skolarus T, Gao F . The role of lymphovascular space invasion in renal cell carcinoma as a prognostic marker of survival after curative resection. Urol Oncol. 2009; 29(6):738-44. DOI: 10.1016/j.urolonc.2009.07.034. View

Cohen H, McGovern F . Renal-cell carcinoma. N Engl J Med. 2005; 353(23):2477-90. DOI: 10.1056/NEJMra043172. View

Zubac D, Bostad L, Gestblom C, Kihl B, Seidal T, Wentzel-Larsen T . Renal cell carcinoma: a clinicopathological follow-up study after radical nephrectomy. Scand J Urol Nephrol. 2007; 41(3):191-7. DOI: 10.1080/00365590601016552. View

Crepel M, Isbarn H, Capitanio U, Liberman D, Jeldres C, Sun M . Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?. Urology. 2009; 74(4):842-5. DOI: 10.1016/j.urology.2009.02.013. View

Tickoo S, Gopalan A . Pathologic features of renal cortical tumors. Urol Clin North Am. 2008; 35(4):551-61. DOI: 10.1016/j.ucl.2008.07.001. View

Ornellas A, Andrade D, Ornellas P, Wisnescky A, Schwindt A . Prognostic factors in renal cell carcinoma: analysis of 227 patients treated at the Brazilian National Cancer Institute. Int Braz J Urol. 2012; 38(2):185-94. DOI: 10.1590/s1677-55382012000200006. View

Ljungberg B, Alamdari F, Stenling R, Roos G . Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol. 1999; 36(6):565-9. DOI: 10.1159/000020049. View

10.

Waldert M, Klatte T, Haitel A, Ozsoy M, Schmidbauer J, Marberger M . Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol. 2009; 57(4):661-5. DOI: 10.1016/j.eururo.2009.05.009. View

11.

Steffens S, Roos F, Janssen M, Becker F, Steinestel J, Abbas M . Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Virchows Arch. 2014; 465(4):439-44. DOI: 10.1007/s00428-014-1648-9. View

12.

Teloken P, Thompson R, Tickoo S, Cronin A, Savage C, Reuter V . Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol. 2009; 182(5):2132-6. PMC: 4169873. DOI: 10.1016/j.juro.2009.07.019. View

13.

Keegan K, Schupp C, Chamie K, Hellenthal N, Evans C, Koppie T . Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol. 2012; 188(2):391-7. PMC: 3714400. DOI: 10.1016/j.juro.2012.04.006. View

14.

Leibovich B, Lohse C, Crispen P, Boorjian S, Thompson R, Blute M . Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010; 183(4):1309-15. DOI: 10.1016/j.juro.2009.12.035. View

15.

Lam J, Leppert J, Figlin R, Belldegrun A . Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2004; 6(1):7-18. DOI: 10.1007/s11934-005-0062-x. View

16.

Furge K, Lucas K, Takahashi M, Sugimura J, Kort E, Kanayama H . Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res. 2004; 64(12):4117-21. DOI: 10.1158/0008-5472.CAN-04-0534. View

17.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

18.

Minervini A, Serni S, Tuccio A, Siena G, Vittori G, Masieri L . Simple enucleation versus radical nephrectomy in the treatment of pT1a and pT1b renal cell carcinoma. Ann Surg Oncol. 2011; 19(2):694-700. DOI: 10.1245/s10434-011-2003-x. View

19.

Stec R, Grala B, Maczewski M, Bodnar L, Szczylik C . Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res. 2009; 28:134. PMC: 2764641. DOI: 10.1186/1756-9966-28-134. View

20.

Stewart G, OMahony F, Powles T, Riddick A, Harrison D, Faratian D . What can molecular pathology contribute to the management of renal cell carcinoma?. Nat Rev Urol. 2011; 8(5):255-65. DOI: 10.1038/nrurol.2011.43. View